N-(tert-butoxycarbonyl)-2,2-dimethyl-4-(4-hydroxyphenyl)-1,3-oxazolidine | 143817-58-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 英文名称: N-(tert-butoxycarbonyl)-2,2-dimethyl-4-(4-hydroxyphenyl)-1,3-oxazolidine
• 英文别名: tert-butyl (S)-4-(4-hydroxybenzyl)-2,2-dimethyloxazolidine-3-carboxylate；N-Boc-N,O-isopropylidene-L-tyrosinol；(S)-4-(4-Hydroxy-benzyl)-2,2-dimethyl-oxazolidine-3-carboxylic acid tert-butyl ester；(S)-4-(4-hydroxybenzyl)-2,2-dimethyloxazolidine-3-carboxylic acid tert-butyl ester；tert-butyl (4S)-4-[(4-hydroxyphenyl)methyl]-2,2-dimethyl-1,3-oxazolidine-3-carboxylate
• CAS: 143817-58-7
• 化学式: C₁₇H₂₅NO₄
• 分子量: 307.39
• InChiKey: KHUOWDLRIVJOIV-ZDUSSCGKSA-N

物化性质

• 沸点：
  423.7±35.0 °C(Predicted)
• 密度：
  1.125±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  22
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.59
• 拓扑面积：
  59
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  N-(tert-butoxycarbonyl)-2,2-dimethyl-4-(4-hydroxyphenyl)-1,3-oxazolidine 在 lithium chloride 、 lead(II) chloride RuCl2(1,3-dimesityl-imidazolidin-2-yl)(PCy3)(=CHPh) 、 4-二甲氨基吡啶 、 sodium chlorite 、 potassium dihydrogenphosphate 、 9-borabicyclo[3.3.1]nonane dimer 、 四(三苯基膦)钯 、 2-甲基-2-丁烯 、 四甲基乙二胺 、 四氯化钛 、 戴斯-马丁氧化剂 、 三乙胺 、 N,N'-二环己基碳二亚胺 、 锌 作用下， 以 四氢呋喃 、 二氯甲烷 、 水 、 甲苯 、 叔丁醇 为溶剂， 反应 51.0h， 生成
  参考文献：
  名称：

  RCM-Based Synthesis of a Variety of β-C-Glycosides and Their in Vitro Anti-Solid Tumor Activity

  摘要：

  The synthesis of a number of biologically relevant C-glycosides has been carried out through the use of an esterification-ring-closing metathesis (RCM) strategy. The required acid precursors were readily prepared via a number of standard chemical transformations followed by dehydrative coupling of these acids with several olefin alcohols 1 to yield the precursor esters 3 in excellent yield. Methylenation of the esters 3 was followed by RCM and in situ hydroboration-oxidation of the formed glycals to furnish the protected beta-C-glycosides 6 in good overall yield. Several examples were converted to the corresponding C-glycoglycerolipids 17 and subsequently screened against solid-tumor cell lines for in vitro differential cytotoxicity.

  DOI：

  10.1021/jo040254t
• 作为产物：
  描述：

  Boc-L-酪氨酸甲酯 在 sodium tetrahydroborate 、 对甲苯磺酸 、 lithium chloride 作用下， 以 四氢呋喃 、 丙酮 为溶剂， 反应 76.0h， 生成 N-(tert-butoxycarbonyl)-2,2-dimethyl-4-(4-hydroxyphenyl)-1,3-oxazolidine
  参考文献：
  名称：

  AZT的S-酰基-2-硫代乙基芳基磷酸三酯衍生物：合成，抗病毒活性和稳定性研究。

  摘要：

  报道了带有修饰的1-酪氨酸残基的3'-叠氮基2'，3'-二脱氧胸苷（AZT）的磷酸三酯衍生物的合成，抗病毒活性和稳定性研究。这些化合物是通过亚磷酰胺（P（III））化学方法从适当的芳基前体获得的。评估了所有衍生物的体外抗HIV活性，在各种细胞培养实验中，它们似乎都是HIV-1复制的有效抑制剂，EC（50）值介于微摩尔和纳摩尔之间，尤其是在胸苷激酶中缺陷（TK（-））细胞，显示其充当单核苷酸前药的能力。这些混合的单核苷芳基磷酸三酯的拟议分解过程依次涉及酯酶和磷酸二酯酶的水解。

  DOI：

  10.1021/jm021016y

文献信息

• The total synthesis of the diepoxycyclohexanone antibiotic aranorosin and novel synthetic analogues
  作者：Alexander McKillop、Lee McLaren、Richard J. K. Taylor、Robert J. Watson、Norman J. Lewis

  DOI：10.1039/p19960001385

  日期：——

  A short synthesis of the novel antibiotic aranorosin in chiral form is described which employs (i) a novel hypervalent iodine-mediated oxidative hydroxylation of a tyrosinal derivative and (ii) a stereocontrolled cis-bisepoxidation in the key steps. A similar procedure was employed to prepare 6′-epiaranorosin, and hence establish the stereochemistry of the natural compound, and to prepare novel aranorosin

  描述了手性形式的新型抗生素阿糖胞苷的简短合成，其在关键步骤中采用了（i）酪氨酸衍生物的新型高价碘介导的氧化羟基化作用和（ii）立体控制的顺式-双环氧化。采用相似的方法制备6'-表皮阿糖胞苷，从而建立天然化合物的立体化学，并制备新的阿糖胞苷类似物。描述了一种有机金属路线，该路线产生了脱酰胺基芳族松香。
• ARYL AMINO ACID DERIVATIVES AS INHIBITORS FOR TREATING INFLAMMATION
  申请人：Sandanayaka Vincent

  公开号：US20080033024A1

  公开（公告）日：2008-02-07

  The present invention relates to a chemical genus of 3-(triaryl)-2-aminopropanol derivative inhibitors of LTA4H (leukotriene A4 hydrolase) useful for the treatment and prevention of inflammatory diseases and disorders. The compounds have general formula III: A particular embodiment is

  本发明涉及一种化学类别的3-(三芳基)-2-氨基丙醇衍生物，它们是LTA4H (白三烯A4水解酶)的抑制剂，可用于治疗和预防炎症性疾病和紊乱。这些化合物具有通用的化学式III:一种特定的实施方式是
• Diversity oriented synthesis of chromene-xanthene hybrids as anti-breast cancer agents
  作者：M. Srinivas Lavanya Kumar、Jyotsana Singh、Sudipta Kumar Manna、Saroj Maji、Rituraj Konwar、Gautam Panda

  DOI：10.1016/j.bmcl.2017.12.065

  日期：2018.2

  A diverse library of chromene-xanthene hybrids were synthesized through intramolecular Friedel-Crafts reaction of the arenoxy carbinols. Examples include first incorporation of amino acid tyrosine into xanthene skeletons with polar functionalities. A careful structural evaluation revealed that tyrosine crafted chromene-xanthene hybrids exhibited good activities against breast cancer cell lines MCF-7

  通过苯甲氧基甲醇的分子内Friedel-Crafts反应合成了色烯-x吨杂种的多样化文库。实例包括首先将氨基酸酪氨酸掺入具有极性官能团的x吨骨架中。仔细的结构评估表明，酪氨酸精制的色烯-x吨杂种对乳腺癌细胞系MCF-7，MDA-MB-231表现出良好的活性。铅化合物16在G1期表现出明显的细胞周期停滞，并诱导MDA-MB-231细胞凋亡。
• Aminoalcohol derivatives and their use as beta 3 adrenergic agonists
  申请人：Fujisawa Pharmaceutical Co. Ltd.

  公开号：US20020143034A1

  公开（公告）日：2002-10-03

  A compound of the formula (I): 1 wherein X 1 is bond or —OCH 2 —; X 2 is —(CH 2 ) n —, in which n is 1, 2 or 3; X 3 is bond, —O—, —S—, —OCH 2 —, or —NH—; R 1 is phenyl or pyridyl each of which may have one or two substituent(s) selected from the group consisting of hydroxy, halogen, etc.; R 2 is hydrogen, (lower)alkoxycarbonyl, etc.; R 3 is hydroxy(lower)alkyl; halo(lower)alkyl, etc.; R 4 is aryl or unsaturated heterocyclic group, each of which may have one or two substituent(s) selected from the group consisting of lower alkyl, hydroxy, carbamoyl, halogen, lower alkoxy, etc.; and a salt thereof which is useful as a medicament.

  该化合物的结构式如下：其中X1是化学键或—OCH2—；X2是—(CH2)n—，其中n为1、2或3；X3是化学键，—O—，—S—，—OCH2—或—NH—；R1是苯基或吡啶基，每个基上可能有一个或两个亚基，如羟基、卤素等；R2是氢、（低）烷氧羰基等；R3是羟基（低）烷基、卤代（低）烷基等；R4是芳基或不饱和杂环基，每个基上可能有一个或两个亚基，如低烷基、羟基、氨基甲酰基、卤素、低烷氧基等；以及其盐，可用作药物。
• Aminoalcohol derivatives
  申请人：——

  公开号：US20040138462A1

  公开（公告）日：2004-07-15

  The present invention relates to a compound formula wherein R 1 is phenyl, pyridyl, etc., each of which may be substituted with one or two substituent(s); R 2 is hydrogen, an amino protective group, etc.; R 3 and R 4 are each independently hydrogen, lower alkyl or hydroxy(lower)alkyl; R 5 is aryl, ar(lower)alkyl, etc., each of which may be substituted with one, two or three substituent(s); R 8 is hydrogen or halogen, X is a single bond or O—CH 2 —, and n is 0, 1 or 2, or a salt thereof. The compound [I] of the present invention and pharmaceutically acceptable salts thereof are useful for the prophylactic and/or the therapeutic treatment of pollakiurea or urinary incontinence. 1

  本发明涉及一种化合物配方，其中R1是苯基，吡啶基等，每个基团可以用一个或两个取代基取代；R2是氢，氨基保护基等；R3和R4各自独立地是氢，低碳基或羟基（低）碳基；R5是芳基，芳（低）碳基等，每个基团可以用一个、两个或三个取代基取代；R8是氢或卤素，X是单键或O-CH2-，n为0、1或2，或其盐。本发明的化合物[I]及其药学上可接受的盐对预防和/或治疗多尿或尿失禁非常有用。